0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover8073.39%IV-288.35%PremiumJul 19, 2024Expiry Date2.97Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8980Delta0.2134Gamma0.34Leverage Ratio-1.9322Theta0.0000Rho-0.31Eff Leverage0.0000Vega
Gossamer Bio Stock Discussion
loading...
loading...
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
No comment yet